Literature DB >> 14607993

The cardio-renal anaemia syndrome: does it exist?

Donald Silverberg1, Dov Wexler, Miriam Blum, Yoram Wollman, Adrian Iaina.   

Abstract

Many patients in our nephrology department who have anaemia and chronic kidney insufficiency (CKI) show evidence of congestive heart failure (CHF). This triad of anaemia, CKI and CHF is known as the cardio-renal anaemia syndrome. The three conditions form a vicious circle, in which each condition is capable of causing or being caused by another. Anaemia can increase the severity of CHF and is associated with a rise in mortality, hospitalization and malnutrition. Anaemia can also further worsen renal function and cause a more rapid progression to dialysis than is found in patients without anaemia. Uncontrolled CHF can cause rapid deterioration of renal function and anaemia. CKI can also cause anaemia, as well as worsen the severity of CHF, and is associated with increased mortality and hospitalization in patients with CHF. Aggressive therapy against CHF with all the conventional medications at the accepted doses often fails to improve the CHF if anaemia is also present but is not treated. In studies in which the anaemia was corrected with s.c. erythropoietin and, in some cases, with i.v. iron, however, the cardiac function improved, as assessed by measurement of the left ventricular ejection fraction and oxygen utilization during maximal exercise. Symptomatic patient functioning improved, as monitored by shortness of breath and fatigue on exertion, and the need for hospitalization and oral and i.v. diuretics markedly decreased. The quality of life, as judged by different criteria, also improved. The glomerular filtration rate, which fell rapidly when the anaemia was untreated, stabilized in patients when their anaemia was treated. Nephrologists need to assess the cardiac status of all patients with CKI carefully, and this includes an echocardiogram along with possibly measuring the levels of B-type natriuretic peptide. Nephrologists also need to use the indicated agents for CHF at the recommended doses, while cardiologists and internists need to be more aware of the importance and lethal effects of even mild anaemia and the benefits of its treatment in CHF and CKI. Cooperation between these specialists will allow better and much earlier treatment of the anaemia, CHF and CKI, and prevent the deterioration of all three conditions.

Entities:  

Mesh:

Year:  2003        PMID: 14607993     DOI: 10.1093/ndt/gfg1084

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  29 in total

1.  Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Authors:  Ana de Lurdes Agostinho Cabrita; Ana Pinho; Anabela Malho; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana Paula Silva; Pedro Leão Neves
Journal:  Int Urol Nephrol       Date:  2010-07-17       Impact factor: 2.370

2.  Cardio-renal interaction: impact of renal function and anemia on the outcome of chronic heart failure.

Authors:  Hisashi Kimura; Shinya Hiramitsu; Kenji Miyagishima; Kazumasa Mori; Ryuji Yoda; Shigeru Kato; Yasuchika Kato; Shin-ichiro Morimoto; Hitoshi Hishida; Yukio Ozaki
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

3.  Altered expression of intestinal duodenal cytochrome b and divalent metal transporter 1 might be associated with cardio-renal anemia syndrome.

Authors:  Yoshiro Naito; Hisashi Sawada; Makiko Oboshi; Keisuke Okuno; Seiki Yasumura; Yoshitaka Okuhara; Akiyo Eguchi; Koichi Nishimura; Yuko Soyama; Masanori Asakura; Masaharu Ishihara; Takeshi Tsujino; Tohru Masuyama
Journal:  Heart Vessels       Date:  2017-07-01       Impact factor: 2.037

4.  The cardiomyopathy of iron deficiency.

Authors:  Nikita Hegde; Michael W Rich; Charina Gayomali
Journal:  Tex Heart Inst J       Date:  2006

5.  A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.

Authors:  Tadao Akizawa; Masaomi Nangaku; Takuhiro Yamaguchi; Masanobu Arai; Ryosuke Koretomo; Atsushi Matsui; Hideki Hirakata
Journal:  Am J Nephrol       Date:  2019-01-30       Impact factor: 3.754

6.  Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins.

Authors:  Enyu Imai; Ryohei Yamamoto; Hiromichi Suzuki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2010-06-30       Impact factor: 2.801

Review 7.  [Anemia and iron deficiency in the elderly. Prevalence, diagnostics and new therapeutic options].

Authors:  G Röhrig; W Doehner; R M Schaefer; R J Schulz
Journal:  Z Gerontol Geriatr       Date:  2012-04       Impact factor: 1.281

8.  Relationship between renal function at the time of percutaneous coronary intervention and prognosis in ischemic heart disease patients.

Authors:  Daijo Inaguma; Miho Tatematsu; Hibiki Shinjo; Sachiyo Suzuki; Tomoko Mishima; Shinichiro Inaba; Kei Kurata; Yukio Yuzawa; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

9.  Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice.

Authors:  Gabriel Melo de Oliveira; Tshaca Mahatma da Silva; Wanderson Silva Batista; Marcello Franco; Nestor Schor
Journal:  Parasitol Res       Date:  2009-09-26       Impact factor: 2.289

10.  Cardio-renal anemia syndrome.

Authors:  G Efstratiadis; D Konstantinou; I Chytas; G Vergoulas
Journal:  Hippokratia       Date:  2008-01       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.